BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Exciting New Cancer Company, Angiogen, To Present At Midwest Venture Summit


10/19/2005 5:10:08 PM

CHICAGO, May 16 /PRNewswire/ -- Angiogen announced today that Mark Arizmendi, President, will be presenting at the Midwest Venture Summit on May 20, 2005, at the Chicago Marriott Magnificent Mile located at 540 North Michigan Avenue, Chicago. Mr. Arizmedi's presentation will focus on the company, its products and its clinical progress.

About Angiogen

Angiogen is a privately held biopharmaceutical discovery company developing novel therapies for treating cancerous solid, vascular tumors. Angiogen's scientific team has world-recognized expertise and experience in angiogenesis inhibition, especially as it relates to the disease of cancer. Angiogen's first therapy, currently in a Phase I clinical trial, is based upon combining two classes of FDA approved drugs into one anti-angiogenesis cancer- fighting treatment. Three major biopharmaceutical companies have provided support for Angiogen's clinical research. Angiogen continues to explore other diagnostic tests and drug candidates related to its work in angiogenesis field offering hope to the approximately 5 million people worldwide who will die annually from metastatic cancer (555,000 in US). For additional information on Angiogen, please visit our Website at: http://www.angiogenesis.com/ .

This press release contains forward-looking statements that involve a high degree of technological, regulatory, and competitive risks and uncertainties inherent in early stage biopharmaceutical companies.

Angiogen

CONTACT: Dorene Lynch for Angiogen, +1-847-754-7815, or Fax,+1-847-864-3291, dlynch@angiogenesis.com



Read at BioSpace.com

Angiogen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES